Karyopharm Therapeutics Inc.

Form 4

September 30, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

OMB APPROVAL

burden hours per

response...

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Czernik Marcin

2. Issuer Name and Ticker or Trading Symbol

Karyopharm Therapeutics Inc.

Issuer

below)

(Check all applicable)

5. Relationship of Reporting Person(s) to

(Last)

(First) (Middle) 3. Date of Earliest Transaction

Director Officer (give title

_X__ 10% Owner __ Other (specify

SIMOU MENARDOU 8,, RIA **COURT 8, OFFICE 101**

> (Street) 4. If Amendment, Date Original

[KPTI]

Filed(Month/Day/Year)

(Month/Day/Year)

09/26/2014

6. Individual or Joint/Group Filing(Check

Applicable Line)

Form filed by One Reporting Person _X_ Form filed by More than One Reporting

Person

6015 LARNACA, G4

(City)	(State) (2	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	(A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
COMMON STOCK	09/26/2014		S	12,480	D	\$ 41.8941 (1)	2,888,037	I	See Footnotes (2) (3) (4)
COMMON STOCK	09/26/2014		S	25,059	D	\$ 42.4434 (1)	2,862,978	I	See Footnotes (2) (3) (4)
COMMON STOCK	09/26/2014		S	12,261	D	\$ 43.3874 (1)	2,850,717	I	See Footnotes (2) (3) (4)
COMMON	09/26/2014		S	200	D	\$ 44 (1)	2,850,517	I	See

STOCK Footnotes (2) (3) (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	.	ate	7. Titl Amou Under Securi (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owno Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
reporting Owner Name / Namess	Director	10% Owner	Officer	Other			
Czernik Marcin SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4		X					
Hadjimichael Andreas SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4		X					
Hadjimichael Amalia SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4		X					

Signatures

Marcin Czernik, by /s/ Simon Prisk, as attorney-in fact by power of attorney

**Signature of Reporting Person

Date

Reporting Owners 2

Edgar Filing: Karyopharm Therapeutics Inc. - Form 4

/s/ Andreas Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney

09/30/2014

**Signature of Reporting Person

Date

/s/ Amalia Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney

09/30/2014

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The prices reported in the first three rows of Column 4 are weighted average prices. The 12,480 shares referred to in the first row in Column 4 were sold at prices ranging from \$ 41.57 to \$ 41.99, inclusive. The 25,059 shares referred to in the second row in Column 4 were sold at prices ranging from \$ 42.00 to \$42.99, inclusive. The 12,261 shares referred to in the third row in Column 4 were sold at prices ranging from \$ 43.00 to \$43.90, inclusive. The 200 shares referred to in the fourth row in Column 4 were sold at the price indicated. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and

Shares of Common Stock are owned directly by Plio Limited ("Plio"), which holds less than 10% of the outstanding Common Stock of

- (1) prices ranging from \$ 43.00 to \$43.90, inclusive. The 200 shares referred to in the fourth row in Column 4 were sold at the price indicated. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth above.
- the issuer. Plio's directors, Marcin Czernik, Andreas Hadjimichael and Amalia Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Plio. Gregory Jankilevitsch, the sole shareholder of Plio, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Plio. The shares owned by Plio do not include the shares of the issuer's Common Stock held by Chione Limited, which has the same directors as Plio.
- Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed, except, with respect to any person, to the extent of the pecuniary interest of such person in such securities.
- Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

Remarks:

Exhibit Index Exhibit 24.1 - Power of Attorney, dated November 5, 2013, made by Marcin Czernik and Plio Limited in favor

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3